This case adds favorable evidence to the pathogenic role of aβ2GPI IgA in arterial thrombosis, highlights the potential efficacy of antiplatelet therapy in non-criteria aPLs-associated APS, challenges the conventional anticoagulation-centered paradigm, and provides novel insights into individualized management for this subgroup. Here, CD79A is linked to autoimmune polyendocrinopathy.